cps

:   counts per second

HTS

:   high‐throughput screening

IL

:   interleukin

ITK

:   interleukin‐2‐inducible T‐cell kinase

KD

:   kinase domain

MOA

:   mechanism of action

NHS

:   *N*‐hydroxysuccinimide

SHG

:   second‐harmonic generation

SPR

:   surface plasmon resonance

WT

:   wild‐type

Protein kinases are the largest enzyme family encoded by the human genome and are comprised of over 500 members [1](#feb412489-bib-0001){ref-type="ref"}. Pharmacological agents directed to them have high potential to treat a number of diseases, spurring numerous lines of research [2](#feb412489-bib-0002){ref-type="ref"}. The overall structure of the catalytic domain of protein kinases is highly conserved [3](#feb412489-bib-0003){ref-type="ref"}. The sequence and the structural topologies of ATP‐binding sites of kinases in the active conformation are highly similar, with key residues optimally aligned for catalysis [4](#feb412489-bib-0004){ref-type="ref"}. Accordingly, the conserved ATP‐binding pocket creates significant difficulties for designing selective kinase inhibitors [5](#feb412489-bib-0005){ref-type="ref"}. In physiological conditions, most kinases exist in equilibrium between active and inactive conformational states [4](#feb412489-bib-0004){ref-type="ref"}. Inhibitors that stabilize an inactive conformation generally tend to show higher selectivity [6](#feb412489-bib-0006){ref-type="ref"}. High‐throughput screens (HTS) of protein kinases are commonly employed to identify kinase inhibitor candidates. These screens provide hits that inhibit the kinase activity but do not report on the resulting conformational state of the target. Thus, it is important for selectivity considerations to further identify those compounds from the HTS hits that stabilize inactive conformations before moving to crystallography. Second‐harmonic generation (SHG) has emerged as a technique for real‐time detection and measurement of protein conformational changes in solution and is broadly applicable across many target classes [7](#feb412489-bib-0007){ref-type="ref"}, [8](#feb412489-bib-0008){ref-type="ref"}, [9](#feb412489-bib-0009){ref-type="ref"}, [10](#feb412489-bib-0010){ref-type="ref"}, [11](#feb412489-bib-0011){ref-type="ref"}. The method is based on tethering proteins labeled with an SHG‐active dye to a surface such as a supported lipid bilayer membrane. SHG is highly sensitive to the orientation of the SHG‐active molecules, permitting the study of conformational changes in the target protein (Fig. [1](#feb412489-fig-0001){ref-type="fig"}).

![Schematic for protein conformational change detection by SHG. Incident laser light strikes the surface and through total internal reflection creates an evanescent wave. Labeled protein is bound to the surface, and the measured SHG signal intensity depends on the average, net orientation of the dye label relative to the surface normal (*z*‐axis). A conformational change that alters the orientational distribution of the label in space or time results in a change in SHG signal intensity. A decrease in SHG signal intensity is caused by the dye moving more perpendicular to the *z*‐axis, while an increase in SHG signal intensity is caused by the dye moving more parallel to the *z*‐axis. In this way, different conformational states of a protein produce different SHG signals.](FEB4-8-1412-g001){#feb412489-fig-0001}

In this report, we have developed an SHG assay for selection of inactive conformation inhibitors to Tec family tyrosine kinase, interleukin (IL)‐2‐inducible T‐cell kinase (ITK). ITK is expressed in T cells, mast cells, and NK cells, and it plays an important role in the production of cytokines such as IL‐2, IL‐4, IL‐5, and IL‐13 [12](#feb412489-bib-0012){ref-type="ref"}, [13](#feb412489-bib-0013){ref-type="ref"}. Due to this role of ITK in T cells, inhibition of the kinase could offer the potential for treating T‐cell‐mediated inflammatory diseases [14](#feb412489-bib-0014){ref-type="ref"}, [15](#feb412489-bib-0015){ref-type="ref"}, [16](#feb412489-bib-0016){ref-type="ref"}.

Materials and methods {#feb412489-sec-0002}
=====================

Materials {#feb412489-sec-0003}
---------

Biacore T200 and 4000 optical biosensors and NTA sensor chips were obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK).

ADP‐Glo™ Kinase Assay kit which contains ADP‐Glo™ Reagent, kinase detection reagent, ATP, and ADP was purchased from Promega (Madison, WI, USA).

Biodesy Delta 384‐well plates and the SHG‐active dye, SHG2‐maleimide (thiol reactive), were made available by Biodesy, Inc.

Tool compounds {#feb412489-sec-0004}
--------------

Known inactive conformation inhibitors for ITK, BMS‐509744 [17](#feb412489-bib-0017){ref-type="ref"}, [18](#feb412489-bib-0018){ref-type="ref"} (compound *A*), Pfizer compound 9 [19](#feb412489-bib-0019){ref-type="ref"} (compound *C*, allosteric binder) and Pfizer compound 40 [20](#feb412489-bib-0020){ref-type="ref"} (compound *D*, covalent binder; Fig. [2](#feb412489-fig-0002){ref-type="fig"}), were selected as positive control compounds for SHG assay development. To expand the tool compounds, two more inactive conformational binders were synthesized from two of the known inactive conformational binders above, as follows. Compound *B* was synthesized by deleting the groups of compound *A* that are exposed to solvent, and compound *E* was synthesized by converting the acryloyl group of compound *D* to an acetyl group, rendering this molecule noncovalent. In addition, we selected staurosporine (compound *F*), GSK compound 13 [21](#feb412489-bib-0021){ref-type="ref"} (compound *G*), Genentech compound 19 [22](#feb412489-bib-0022){ref-type="ref"} (compound *H*), Sanofi US compound [23](#feb412489-bib-0023){ref-type="ref"}, [24](#feb412489-bib-0024){ref-type="ref"} (compound *I*), and Genentech GNE‐9822 [25](#feb412489-bib-0025){ref-type="ref"} (compound *J*) as active conformation inhibitors, and imatinib [26](#feb412489-bib-0026){ref-type="ref"} (compound *K*), GW‐2580 [27](#feb412489-bib-0027){ref-type="ref"} (compound *L*), PLX‐4720 [28](#feb412489-bib-0028){ref-type="ref"} (compound *M*) and gefitinib [29](#feb412489-bib-0029){ref-type="ref"} (compound *N*) as nonbinders.

![Chemical structures of reference compounds. Compounds *A*--*E* are inactive conformation binders, compounds *F*--*J* are active conformation binders, and compounds *K*--*N* are nonbinders.](FEB4-8-1412-g002){#feb412489-fig-0002}

Cloning, expression, and purification of human tyrosine kinase {#feb412489-sec-0005}
--------------------------------------------------------------

The His~6~‐tagged human wild‐type ITK kinase domain (WT ITK) was expressed from the pVL1393/His‐hITK KD vector. This vector was constructed by cloning the human ITK KD from the human ITK full‐length cDNA (OriGene, Rockville, MD, USA) into pVL1393 (Thermo Fisher Scientific, Waltham, MA, USA) using primers that encoded an N‐terminal His~6~‐tag.

His~6~‐tagged human mutant ITK KD (ITK Mutant A) was expressed from the pVL1393/His‐hITK KD MutA vector. This vector was constructed by PCR‐based site‐directed mutagenesis of pVL1393/His‐hITK KD to incorporate the following changes to the native sequence: one native solvent‐exposed amino acid on the αC‐helix was substituted with a cysteine, and the native cysteines (C442, C477) in the WT enzyme were mutated to serines. The myc‐tagged human YopH was cloned utilizing primers that encoded an N‐terminal myc‐tag to amplify human YopH from commercially available cDNA (GenScript, Piscataway, NJ, USA). The resulting PCR product was cloned into pVL1393 resulting in expression vector pVL1393/myc‐YopH. All plasmids were confirmed by sequence analysis.

Recombinant baculovirus was produced using the BaculoGold Transfection Kit (BD Biosciences, San Jose, CA, USA). For protein production, the cells were coinfected with either pVL1393/His‐hITK KD or pVL1393/His‐hITK KD MutA baculovirus, and pVL1393/YopH baculovirus at an appropriate rate to ensure uniform dephosphorylation. Cells were harvested by centrifugation 72 h postinfection and stored at −80 °C.

Wild‐type ITK and ITK Mutant A were purified from cell lysate on Ni‐NTA Superflow (Qiagen, Germantown, MD, USA) and eluted with 50 m[m]{.smallcaps} HEPES, pH 8.0, 150 m[m]{.smallcaps} NaCl, and 500 m[m]{.smallcaps} imidazole. The WT ITK and ITK Mutant A containing fractions were pooled, respectively, and further purified by ion exchange over Q Sepharose Fast Flow (GE Healthcare), followed by gel filtration over a Superdex 200 10/300 GL (GE Healthcare). The final protein buffer contained 50 m[m]{.smallcaps} HEPES, pH 8.0, 500 m[m]{.smallcaps} NaCl, 10% glycerol, and 1 m[m]{.smallcaps} DTT. The protein was concentrated to \~ 2.5 mg·mL^−1^, flash‐frozen with liquid nitrogen, and stored at −80 °C.

Dephosphorylation of WT ITK and ITK Mutant A by YopH was confirmed by western blotting using the monoclonal phosphotyrosine antibody clone 4G10 from Merck Millipore (Darmstadt, Germany).

ADP‐Glo™ inhibitory assay {#feb412489-sec-0006}
-------------------------

Enzymatic activity of WT ITK and ITK Mutant A was measured using the ADP‐Glo™ Kinase Assay [30](#feb412489-bib-0030){ref-type="ref"} (Promega). Activity measurements were taken following the manufacturer\'s protocols. The ADP production was measured in assay buffer (25 m[m]{.smallcaps} HEPES, pH 7.5, 25 m[m]{.smallcaps} KCl, 10 m[m]{.smallcaps} MgCl~2~, 1 m[m]{.smallcaps} DTT, 0.005% Tween 20, 0.1% BSA) in a 384‐well plate format. The reactions were carried out at room temperature in a total volume of 5 μL for 60 min with 70 μ[m]{.smallcaps} ATP and at excess substrate (SLP76 [18](#feb412489-bib-0018){ref-type="ref"}) concentrations. ADP‐Glo™ reagent was added at room temperature for 40 min to stop the kinase reaction and deplete the unconsumed ATP, leaving only ADP and a very low background of ATP. Furthermore, kinase detection reagent was added to convert ADP to ATP and introduce luciferase and luciferin to detect ATP. The plate was read by a Paradigm (Molecular Devices, LLC, Sunnyvale, CA, USA) in luminescent mode.

SPR assay {#feb412489-sec-0007}
---------

Wild‐type ITK was immobilized onto an NTA sensor chip using the capture coupling method that results in the capture in a nonrandom orientation by the His~6~‐tag prior to amine coupling to produce functional and stable surfaces [31](#feb412489-bib-0031){ref-type="ref"}. The surface of the sensor chip was activated with a mixture of 0.1 mol·L^−1^ *N*‐hydroxysuccinimide and 0.4 mol·L^−1^ *N*‐ethyl‐*N'*‐(dimethylaminopropyl) carbodiimide for 5 min at 10 °C. WT ITK (10 μg·mL^−1^) in running buffer (25 m[m]{.smallcaps} HEPES, pH 7.5, 25 m[m]{.smallcaps} KCl, 10 m[m]{.smallcaps} MgCl~2~, 1 m[m]{.smallcaps} DTT, 0.005% Tween 20) was injected for 10 min. Typical immobilization levels ranged from 2900 to 4900 resonance units.

The compounds were diluted directly into the running buffer containing 5% DMSO. Serially diluted compounds were injected in a separate cycle for 60‐s association followed by 60‐s dissociation at a flow rate of 30 μL·min^−1^. Competition experiments were carried out in the presence of ADP at a 1000 μ[m]{.smallcaps} concentration diluted in the running buffer.

All data analysis was performed using Biacore T200 or Biacore 4000 evaluation software. Sensorgram data were solvent‐corrected and double‐referenced. For kinetic analysis, data were fit to 1 : 1 interaction model. For steady‐state analysis, responses at equilibrium were plotted against the compound concentration and fit to a 1 : 1 Langmuir binding isotherm.

SHG assay protein labeling {#feb412489-sec-0008}
--------------------------

Interleukin‐2‐inducible T‐cell kinase Mutant A was labeled with SHG2‐maleimide (thiol‐reactive dye) in 50 m[m]{.smallcaps} sodium phosphate, pH 6.5, 150 m[m]{.smallcaps} NaCl, and 10% glycerol. One hundred micromolar of protein was incubated with 500 μ[m]{.smallcaps} of dye at room temperature for 90 min. The reactions were then centrifuged at 4 °C for 20 min before the reaction was stopped by removing excess dye by buffer exchange with a Zeba™ column (Thermo Fisher) into storage buffer (50 m[m]{.smallcaps} HEPES, pH 8.0, 500 m[m]{.smallcaps} NaCl, 10% glycerol, 1 m[m]{.smallcaps} DTT). The degree of labeling was measured by UV/Vis spectroscopy and was measured to be 1.3 (dyes/protein). The resulting conjugate, ITK Mutant A‐SHG2, was flash‐frozen in liquid nitrogen and stored at −80 °C until use.

SHG assay for tool compounds using ITK Mutant A‐SHG2 {#feb412489-sec-0009}
----------------------------------------------------

Five microliter of ITK Mutant A labeled with SHG2‐maleimide (ITK Mutant A‐SHG2) was preincubated at room temperature with 20 μ[m]{.smallcaps} compound for 60 min in assay buffer (25 m[m]{.smallcaps} HEPES, pH 7.5, 25 m[m]{.smallcaps} KCl, 10 m[m]{.smallcaps} MgCl~2~, 1 m[m]{.smallcaps} DTT, 0.005% Tween 20). 10 μL of the protein/compound mixture was added to 10 μL of assay buffer on the Ni/NTA bilayer surface. Protein was allowed to tether to the surface through the Ni/NTA:His~6~‐tag interaction at room temperature for 90 min, at which point the SHG signal was measured (Fig. [3](#feb412489-fig-0003){ref-type="fig"}A--D).

![Schematic of the SHG experiment. SHG assay workflow (preincubation and competition methods). (A) Incubate His~6~‐tagged, labeled protein with compound at room temperature to allow binding to come to equilibrium. (B) Inject protein/compound mixture onto the Biodesy Ni/NTA bilayer surface in the wells of a Biodesy Delta 384‐well plate. (C) Allow the capture of the protein/compound to the surface through the Ni/NTA:His~6~‐tag interaction by incubation at room temperature. (D) Measure SHG signal intensity. (E) Wash out unbound protein/compound. (F) Measure SHG signal intensity. (G) Inject a second compound. (H) Measure the change in SHG signal intensity to determine whether the protein has changed conformation.](FEB4-8-1412-g003){#feb412489-fig-0003}

In a competition assay, after SHG readout \#1 (Fig. [3](#feb412489-fig-0003){ref-type="fig"}D), unbound protein and excess compound were washed out, and then, SHG baseline signal was measured (Fig. [3](#feb412489-fig-0003){ref-type="fig"}F). The washed well was then injected with 20 μL of 10 μ[m]{.smallcaps} test compound, and the SHG signal was measured again (Fig. [3](#feb412489-fig-0003){ref-type="fig"}H). The time between measurement of SHG intensity \#2 (Fig. [3](#feb412489-fig-0003){ref-type="fig"}F) and measurement of SHG intensity \#3 (Fig. [3](#feb412489-fig-0003){ref-type="fig"}H) was 5 min.

To calculate the percent change in SHG intensity (% Δ~SHG~), the SHG intensity of readout \#2 (Int~\#2~) was subtracted from the SHG intensity of readout \#3 (Int~\#3~) and then divided by the initial second‐harmonic intensity (Int~\#2~) according to the following equation: $$\%\Delta_{SHG} = {(\text{Int}_{\# 3} - \text{Int}_{\# 2})}/\text{Int}_{\# 2}.$$

SHG assay for binning HTS hits {#feb412489-sec-0010}
------------------------------

The compounds to be analyzed were mixed with 500 n[m]{.smallcaps} ITK Mutant A‐SHG2 and allowed to incubate at room temperature for 60 min. The protein/compound mixtures were added to the Ni/NTA bilayer surface with a 1 : 1 dilution for a final protein concentration of 250 n[m]{.smallcaps} in a 384‐well plate format. Each compound was run at 2.5, 10, and 40 μ[m]{.smallcaps} for lower potency compounds (IC~50~ values ≥ 1 μ[m]{.smallcaps}) or at 0.31, 1.3, and 5.0 μ[m]{.smallcaps} for higher potency compounds (IC~50~ values of \< 1 μ[m]{.smallcaps}). Protein/compound mixtures were allowed to attach to the bilayer surface for 90 min at room temperature, and the SHG signal was then measured (Fig. [3](#feb412489-fig-0003){ref-type="fig"}D). All experiments were performed in triplicate. SHG signal is reported in photon counts per second (cps).

Results {#feb412489-sec-0011}
=======

Characterization of protein and tool compounds {#feb412489-sec-0012}
----------------------------------------------

His~6~‐tagged human ITK KD (WT ITK) was utilized for both the biochemical and surface plasmon resonance (SPR) assays. WT ITK with a cysteine substituted in the αC‐helix (ITK Mutant A) was used for the SHG assay. The engineered Cys residue was inserted in order to conjugate the dye to a site‐specific location that reports on the structural change between the active and inactive conformations of the protein. The amino acid substitutions in ITK Mutant A (C442S/C477S, and Cys substitution on αC‐helix) were shown to have no impact on enzymatic activity (Fig. [4](#feb412489-fig-0004){ref-type="fig"}). To allow the protein to adopt both an active and an inactive conformation, all proteins were coexpressed with the tyrosine phosphatase, YopH, in baculovirus to fully dephosphorylate them. Dephosphorylation was validated by western blot using a monoclonal phosphotyrosine antibody (Fig. [5](#feb412489-fig-0005){ref-type="fig"}). We prepared 14 tool compounds with known biochemical ITK inhibitory activity and binding affinity summarized in Fig. [2](#feb412489-fig-0002){ref-type="fig"} and Table [1](#feb412489-tbl-0001){ref-type="table"}, respectively.

![Enzyme activity of WT ITK and ITK Mutant A. The time course of the phosphorylation reaction of WT ITK (![](FEB4-8-1412-g012.jpg "image")) and ITK Mutant A (![](FEB4-8-1412-g013.jpg "image")) is similar, indicating that the mutations made to the WT sequence do not alter the activity of the resulting mutant protein. Data were recorded for 90 min using ADP‐Glo™ Kinase Assay and are shown as the mean ± SD of triplicate measurements.](FEB4-8-1412-g004){#feb412489-fig-0004}

![SDS/PAGE and western blotting of WT ITK and ITK Mutant A. (A) Purified kinases were analyzed on SDS/PAGE, stained with Coomassie blue. (B) Western blotting results with antiphosphotyrosine. Lanes 1, molecular weight markers; lanes 2, YopH phosphatase untreated full‐length ITK (this was applied as a reference of phosphorylated kinase); lanes 3, dephosphorylated WT ITK; lanes 4, dephosphorylated ITK Mutant A.](FEB4-8-1412-g005){#feb412489-fig-0005}

###### 

Biochemical inhibitory activity and binding affinity of tool compounds

  No    Form        Company       Inhibitor         IC~50~ ([m]{.smallcaps})   *K* ~D~ ([m]{.smallcaps})
  ----- ----------- ------------- ----------------- -------------------------- ---------------------------
  *A*   Inactive    BMS           BMS‐509744        2.5 × 10^−9^               1.3 × 10^−9^
  *B*   Inactive                  Derivative of A   2.6 × 10^−7^               7.5 × 10^−8^
  *C*   Inactive    Pfizer        Comp 9            2.4 × 10^−8^               2.5 × 10^−8^
  *D*   Inactive    Pfizer        Comp 40           8.5 × 10^−9^               NT
  *E*   Inactive                  Derivative of D   4.6 × 10^−7^               1.1 × 10^−6^
  *F*   Active                    Staurosporine     1.3 × 10^−8^               1.2 × 10^−8^
  *G*   Active      GSK           Comp 13           3.5 × 10^−9^               3.6 × 10^−9^
  *H*   Active      Genentech     Comp 19           1.3 × 10^−9^               2.1 × 10^−9^
  *I*   Active      Sanofi US                       1.8 × 10^−9^               1.5 × 10^−9^
  *J*   Active      Genentech     GNE‐9822          1.1 × 10^−9^               3.5 × 10^−9^
  *K*   Nonbinder   Novartis      Imatinib          \> 3.0 × 10^−5^            \> 3.0 × 10^−5^
  *L*   Nonbinder   GSK           GW‐2580           \> 3.0 × 10^−5^            \> 3.0 × 10^−5^
  *M*   Nonbinder   Plexxikon     PLX‐4720          \> 3.0 × 10^−5^            \> 3.0 × 10^−5^
  *N*   Nonbinder   AstraZeneca   Gefitinib         \> 3.0 × 10^−5^            \> 3.0 × 10^−5^

Inhibitory activities and affinities of each compound against His~6~‐tagged human ITK KD (WT ITK) were measured by ADP‐Glo™ Kinase Assay and SPR assay, respectively.

*K* ~D~ of compound *D* was not measured due to covalent inhibitor.

John Wiley & Sons, Ltd

SHG assay development {#feb412489-sec-0013}
---------------------

Interleukin‐2‐inducible T‐cell kinase Mutant A‐SHG2 was preincubated with each of the 14 tool compounds to demonstrate that we could distinguish inactive conformation inhibitors, active conformation inhibitors, and nonbinders by SHG signal differences. A schematic of the assay is shown in Fig. [3](#feb412489-fig-0003){ref-type="fig"}A--D. The results of this panel showed large SHG signal compared to apo protein for compounds *F*,*H*,*I*, and *J* (Fig. [6](#feb412489-fig-0006){ref-type="fig"}), all of which are known active conformation inhibitors. Compound *G* is also an active conformation inhibitor but showed an intermediate SHG signal, which could be due to its lower solubility. All other compounds in the panel showed similar SHG signal intensity to the apo form of the protein. Compounds *A*--*E* are known inactive conformation inhibitors, and compounds *K*--*N* are known nonbinders. These two classes of compounds cannot be distinguished from one another in the current assay setup. However, they can be readily distinguished from the active conformation inhibitors.

![SHG signal of ITK Mutant A‐SHG2 with tool compounds. Compounds *A*--*E* are inactive conformation inhibitors and show low SHG intensity compared to compounds *F*--*J* which are active conformation inhibitors. Compounds *K*--*N* are nonbinders and cannot be distinguished from inactive conformation inhibitors, but are clearly different than active conformation inhibitors. Compound *G* shows an intermediate SHG intensity most likely due to low solubility of this compound. Dashed lines are the respective averages of inactive conformation inhibitors, active conformation inhibitors, and nonbinders. Data are shown as the mean ± SD of duplicate measurements.](FEB4-8-1412-g006){#feb412489-fig-0006}

SHG assay validation {#feb412489-sec-0014}
--------------------

To show that ITK Mutant A‐SHG2 maintained its activity on the surface, compound injection after immobilization of the protein was performed. A schematic of the assay is shown in Fig. [3](#feb412489-fig-0003){ref-type="fig"}A--H. ITK Mutant A‐SHG2 was preincubated with compound *E*, a low‐affinity inactive conformation inhibitor (*K* ~D~ of 1.1 μ[m]{.smallcaps} for WT ITK). The protein/compound mixture was injected onto the Ni/NTA bilayer surface and allowed to tether to the surface. Unbound protein/compound was washed out, and then, a high‐affinity inactive conformation inhibitor (compound *A, K* ~D~ of 1.3 n[m]{.smallcaps} for WT ITK), a high‐affinity active conformation inhibitor (compound *J, K* ~D~ of 3.5 n[m]{.smallcaps} for WT ITK) or buffer, was injected onto the complex on the surface.

Upon compound *A* injection, the SHG signal decreased by 24%, suggesting that more conjugate molecules shifted to the inactive conformation (Fig. [7](#feb412489-fig-0007){ref-type="fig"}). When compound *J* was injected, there was a dramatic increase of 49% in SHG signal, suggesting a switch from the inactive to the active conformation. The observed SHG signal change correlates with the preincubation results in Fig. [6](#feb412489-fig-0006){ref-type="fig"}, which shows relatively low SHG signal for inactive conformation inhibitors and high SHG signal for active conformation inhibitors. The signal changes upon competitive binding with the high‐affinity inhibitor also demonstrate that ITK Mutant A‐SHG2, when stabilized by preincubation with compound *E*, remains functional on the surface. Injection of buffer showed a decrease in the SHG intensity of −1.7% indicating no conformational change.

![ITK Mutant A is free to change conformation when tethered to the Ni/NTA bilayer surface. ITK Mutant A was preincubated with control compound *E* and then tethered to the Ni/NTA bilayer surface. Compound *A* (inactive conformation inhibitor) and compound *J* (active conformation inhibitor) were injected onto compound *E* bound ITK Mutant A on the surface. Observation of a negative SHG intensity change after compound *A* injection, and a positive SHG intensity change after compound *J* injection, suggests movement of the protein into the inactive and active conformations, respectively. Data are shown as the mean ± SD of duplicate measurements.](FEB4-8-1412-g007){#feb412489-fig-0007}

Optimization of protein concentration for a more high‐throughput SHG assay {#feb412489-sec-0015}
--------------------------------------------------------------------------

To develop a high‐throughput SHG screen, we attempted to reduce the labeled protein concentration in the assay to conserve material. During the initial phase of assay development, we incubated 5 μ[m]{.smallcaps} ITK Mutant A‐SHG2 with 20 μ[m]{.smallcaps} compound. This reaction was then diluted 1 : 1 with assay buffer, and the final concentrations of protein and compound were 2.5 and 10 μ[m]{.smallcaps}, respectively. Holding the compound concentration constant, we tested final protein concentrations of 500 and 250 n[m]{.smallcaps}. Both protein concentrations gave similar results with SHG signals of active conformation inhibitors above three times the standard deviation (+3σ) of the signal level (5300 cps) of the protein bound to compound *E* (Fig. [8](#feb412489-fig-0008){ref-type="fig"}). Therefore, we performed the binning experiments at 250 n[m]{.smallcaps} final protein concentration (160 ng per well), and a +3σ difference of the signal bound to compound *E,* the lowest affinity inactive form binder among the tool compounds, was used as a criterion for separation between active conformation inhibitors and inactive conformation inhibitors/nonbinders.

![SHG signal of ITK Mutant A‐SHG2 with compound at two protein concentrations. SHG signals were measured at 250 and 500 n[m]{.smallcaps} of protein with 10 μ[m]{.smallcaps} of compound to find the optimal protein concentration for the binning experiment. The dashed line (5300 cps) corresponds to +3σ of 250 n[m]{.smallcaps} protein with 10 μ[m]{.smallcaps} compound *E*. Data are shown as the mean ± SD of triplicate measurements.](FEB4-8-1412-g008){#feb412489-fig-0008}

Conformational binning of hits from a HTS with the SHG assay {#feb412489-sec-0016}
------------------------------------------------------------

Next, we used the optimized SHG assay to distinguish between active and inactive conformation inhibitors within the set of 105 hits previously identified in a high‐throughput biochemical screen; the screen only identified whether they are inhibitors but did not provide any information about their conformational mechanism of action (MOA). Inhibitory activity of these compounds was lower than 10 μ[m]{.smallcaps}, and most of these binders showed a typical 1 : 1 interaction and stoichiometry by SPR.

The compounds were classified into low potency (IC~50~ values ≥ 1 μ[m]{.smallcaps}) and high potency (IC~50~ values \< 1 μ[m]{.smallcaps}) molecules. Each compound was evaluated at 2.5, 10, and 40 μ[m]{.smallcaps} for low potency or at 0.31, 1.3, and 5.0 μ[m]{.smallcaps} for high potency compounds. The results of the screen showed a clear difference between active and inactive conformation inhibitors (Fig. [9](#feb412489-fig-0009){ref-type="fig"}). Compounds were classified as active conformation inhibitors when the resulting SHG signal was above the +3σ signal (7000 cps) of the control compound (compound *E*) at the highest inhibitor concentration. In contrast, compounds below the +3σ of compound *E* were classified as inactive conformation inhibitors, low‐affinity active conformation inhibitors, or nonbinders. Of 105 compounds, 22 were determined to be inactive conformation inhibitors, weak active conformation inhibitors, or nonbinders. However, based on the HTS assay results and SPR follow‐up (data not shown), all 105 compounds were shown to bind ITK, with the affinity of the weakest binders at \~ 10 μ[m]{.smallcaps}. Therefore, all 22 compounds were neither weak active conformation inhibitors nor nonbinders, suggesting that these compounds with low SHG signal were inactive conformation inhibitors. As examples, SHG signals of J‐31 (IC~50~ of 5.5 μ[m]{.smallcaps} for WT ITK) and J‐95 (IC~50~ of 3.3 μ[m]{.smallcaps} for WT ITK) are shown in Fig. [10](#feb412489-fig-0010){ref-type="fig"}. SHG signals at all concentrations of these compounds are comparable in intensity to compounds *A* and *E*, indicating that they too are inactive conformation inhibitors.

![SHG signal intensity for conformational binning of HTS hits. A total of 105 compounds from the HTS biochemical screen were analyzed with the SHG assay in triplicate. Dashed line (7000 cps) was +3σ of the SHG signal of ITK Mutant A‐SHG2 bound to compound *E* and was used as the cutoff to distinguish between active (![](FEB4-8-1412-g014.jpg "image")) and inactive (![](FEB4-8-1412-g015.jpg "image")) conformation inhibitors. Of the 105 compounds analyzed, 22 bin as inactive conformation inhibitors. Data are shown as the mean ± SD of triplicate measurements at the highest inhibitor concentration (5 or 40 μ[m]{.smallcaps}).](FEB4-8-1412-g009){#feb412489-fig-0009}

![Conformational binning of J‐31 and J‐95 by SHG assay. (A) Chemical structures of J‐31 and J‐95. (B) SHG signals were measured at 2.5, 10, and 40 μ[m]{.smallcaps} of J‐31 or J‐95 and at 10 μ[m]{.smallcaps} of compounds *A*,*E*, or *J*. Control compounds *A* and *E* show low SHG signal intensity compared to control compound *J*. Compounds *A* and *E* are known inactive conformation inhibitors and compound *J* is a known active conformation inhibitor, both bins are clearly distinguished by SHG signal intensity. Test compounds J‐31 and J‐95 show SHG signal intensities similar to control compounds *A* and *E* and can therefore be binned as inactive conformation inhibitors. Data are shown as the mean ± SD of triplicate measurements.](FEB4-8-1412-g010){#feb412489-fig-0010}

Kinase selectivity of ITK inhibitors {#feb412489-sec-0017}
------------------------------------

Having determined by SHG that J‐31 and J‐95 are inactive conformation inhibitors, we next evaluated their selectivity in a broad kinase panel using biochemical assays. We screened against 54 kinases in the DiscoveRx KINOME*scan*® (Eurofins DiscoverX, San Diego, CA, USA) at a concentration of 50 μ[m]{.smallcaps} of J‐31 and 20 μ[m]{.smallcaps} of J‐95. J‐95 was assessed at 20 μ[m]{.smallcaps} due to low solubility. J‐31 only inhibited one kinase (CLK1) at \> 65% and J‐95 only inhibited two kinases (HCK and LCK) at \> 65% (Table [2](#feb412489-tbl-0002){ref-type="table"}), indicating good specificity of these compounds.

###### 

Kinase selectivity of J‐31 and J‐95 as assessed by DiscoveRx KINOME*scan* ^®^

  DiscoveRx gene symbol        Percentage of control binding   
  ---------------------------- ------------------------------- -----
  AKT1                         100                             85
  ASK1                         100                             100
  AURKB                        80                              96
  BMPR1B                       72                              74
  BRAF                         88                              100
  BRK                          100                             100
  CAMK1                        84                              86
  CAMK2A                       97                              100
  CDK2                         90                              100
  CDKL2                        100                             100
  CLK1                         21                              100
  CSNK1D                       79                              98
  DAPK3                        98                              96
  DRAK2                        100                             100
  DYRK2                        68                              100
  EGFR                         100                             47
  EPHA3                        86                              92
  EPHB4                        83                              100
  FES                          89                              100
  FGFR1                        95                              80
  GRK4                         91                              84
  HCK                          86                              33
  IKK‐beta                     63                              100
  IRAK4                        79                              87
  JAK2(JH1 domain‐catalytic)   53                              61
  KIT                          41                              100
  LCK                          98                              29
  MAP4K5                       95                              99
  MARK2                        82                              82
  MAST1                        47                              90
  MEK6                         97                              95
  MERTK                        90                              100
  MRCKA                        98                              100
  NEK3                         63                              79
  p38‐alpha                    87                              97
  PAK4                         100                             94
  PCTK1                        84                              98
  PKAC‐alpha                   93                              97
  PKMYT1                       93                              96
  PLK2                         69                              93
  PRKCH                        100                             100
  PRKD1                        100                             100
  RSK1(Kin.Dom.1‐N‐terminal)   92                              99
  RSK4(Kin.Dom.2‐C‐terminal)   76                              95
  SGK3                         72                              90
  SLK                          100                             100
  SYK                          100                             61
  TAOK1                        100                             91
  TEC                          100                             86
  TIE2                         100                             100
  TRKC                         100                             97
  TSSK1B                       100                             100
  ULK1                         75                              97
  YANK1                        92                              94

J‐31 and J‐95 were screened at 50 and 20 μ[m]{.smallcaps}, and the results for the primary screen binding interactions are reported as a percentage of control binding, where lower numbers indicate stronger hits in the matrix. Values of \< 35% control binding, indicating \> 65% inhibition are considered ?hits'. The hit of J‐31 was CLK1 at 21% control binding, indicating 79% inhibition. The hits of J‐95 were HCK and LCK at 33 and 29% control binding, indicating 67 and 71% inhibition, respectively.

John Wiley & Sons, Ltd

Determination of binding site {#feb412489-sec-0018}
-----------------------------

To help identify potential binding sites on ITK and provide valuable information for further optimization, we used the Biacore assay to examine competition between the inhibitors and ADP. J‐31 and J‐95 bound to ITK in the absence of ADP (*K* ~D~ of 3.4 and 1.0 μ[m]{.smallcaps}, respectively) and did not bind in the presence of ADP (Fig. [11](#feb412489-fig-0011){ref-type="fig"}). Therefore, both compounds would probably be ATP‐site binders that stabilize the inactive conformation of ITK.

![SPR data of J‐31 and J‐95. (A,B) Left: J‐31 and J‐95 were injected on the surface of WT ITK at a range of concentrations (20 μ[m]{.smallcaps} and twofold dilutions thereof). Right: Nonlinear curve fitting using a 1 : 1 Langmuir binding isotherm yielded *K* ~D~ of 3.4 μ[m]{.smallcaps} and 1.0 μ[m]{.smallcaps}. (C,D) J‐31 and J‐95 were injected on the surface of WT ITK at a range of concentrations (20 μ[m]{.smallcaps} and twofold dilutions thereof) in the presence of 1000 μ[m]{.smallcaps} ADP. J‐31 and J‐95 did not bind in the presence of ADP suggesting that both compounds are ATP‐site binders.](FEB4-8-1412-g011){#feb412489-fig-0011}

Discussion {#feb412489-sec-0019}
==========

Second‐harmonic generation is a nonlinear optical technique in which two photons of equal energy are combined by a nonlinear material or molecule to generate one photon with twice the energy [32](#feb412489-bib-0032){ref-type="ref"}, [33](#feb412489-bib-0033){ref-type="ref"}. Recently, the SHG technique has been shown to be a powerful method for studying biomolecular structure and conformational changes. In this study, we developed an SHG‐based assay to identify compounds that stabilized the ITK αC‐helix Glu‐out inactive conformation without the need to determine costructures by X‐ray crystallography. From among a set of 105 HTS hits, we identified 22 inactive conformation inhibitors by excluding compounds with SHG signal comparable to the active conformation inhibitor control.

It is important for precise compound binning that the SHG‐active dye is conjugated at a suitable site on the target protein and that the activity of an immobilized target protein is maintained. Multiple approaches can be used to label proteins. Generally WT proteins can be labeled randomly at lysines through amine‐reactive chemistry. In parallel, mutant proteins with engineered cysteines can be labeled through thiol‐reactive chemistry to introduce dyes to targeted residues. Although most published assays of SHG‐detected conformational changes rely on random labeling [9](#feb412489-bib-0009){ref-type="ref"}, we adopted a site‐specific labeling strategy to distinguish inactive conformation inhibitors. To select the site of the cysteine mutant for introducing the SHG dye, we focused on movements of the αC‐helix. This helix exhibits a large movement between the inactive and active conformations in the reported ITK X‐ray structures (Protein Data Bank ID code: [4L7S](4L7S) [21](#feb412489-bib-0021){ref-type="ref"}, [4MF1](4MF1) [22](#feb412489-bib-0022){ref-type="ref"}, [4PQN](4PQN) [25](#feb412489-bib-0025){ref-type="ref"} for active conformations and [3MJ2](3MJ2) [17](#feb412489-bib-0017){ref-type="ref"}, [4M14](4M14) [19](#feb412489-bib-0019){ref-type="ref"}, [4HCU](4HCU) [20](#feb412489-bib-0020){ref-type="ref"} for inactive conformations). A single cysteine mutant was introduced into the kinase αC‐helix resulting in an SHG assay that reports on the conformational state of the labeled αC‐helix upon binding active or inactive conformation inhibitors. The ITK Mutant A‐SHG2 conjugate was found to discriminate well between the inactive and active conformation inhibitors with a set of 14 tool compounds, proving that site‐specific labeling of an engineered cysteine in the αC‐helix is effective to distinguish active and inactive conformations in this study.

To ascertain whether ITK Mutant A‐SHG2 maintained its activity on the surface during the assay, we ran an order of addition experiment. The SHG assay resolved the displacement of a low‐affinity inactive conformation inhibitor (compound *E, K* ~D~ of 1.1 μ[m]{.smallcaps} for WT ITK) with a high‐affinity inactive conformation inhibitor (compound *A, K* ~D~ of 1.3 n[m]{.smallcaps} for WT ITK) and a high‐affinity active conformation inhibitor (compound *J, K* ~D~ of 3.5 n[m]{.smallcaps} for WT ITK; Fig. [7](#feb412489-fig-0007){ref-type="fig"}). Therefore, ITK can be stably tethered to the surface and produce functional responses, as expected.

Next, we used the SHG assay to select inactive conformation inhibitors from a set of 105 HTS hits. All compounds were previously validated to bind ITK by Biacore, but could not be binned into conformational class without requiring X‐ray cocrystal structure determination. NMR and X‐ray crystallography have been generally used to detect conformational shifts, but these methods have low to mid‐throughput, require large amounts of sample, and are often challenging. In contrast, the SHG assay is very efficient in terms of protein consumption and throughput. For instance, 500 μg of protein would be required for screening about 100 compounds at three concentrations in a triplicate. Moreover, there is no target protein size limitation with SHG. SHG can be a powerful tool, providing information about ligand‐induced conformational changes.

In the assay format described here we did not attempt to quantitatively measure the affinity of compounds as we used an SPR assay instead. Rather, we focused on selecting inactive form binders from hits qualified and validated by SPR and inhibitory assays. Of 105 compounds, 22 compounds were determined by SHG to be inactive conformation inhibitors, providing crucial structural information about the compound MOA and supplementing the typical screening data consisting of potency and affinity routinely measured by orthogonal methods. J‐31 and J‐95 were selected as examples and were evaluated in a broad kinase panel. Both compounds demonstrated high selectivity for ITK.

The identification of a subset of compounds that stabilize the inactive conformation of ITK among a larger pool of hits using an SHG assay creates an opportunity for rapidly developing novel highly selective kinase inhibitors against this kinase and, in principle, any kinase target in a high‐throughput manner. We believe that applying similar SHG‐based assays opens the way to discover high‐selectivity inhibitors across many other members of the kinome and with other protein classes as well.
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